Synectics Investors - SNX

Synectics Investors - SNX

Best deals to access real time data!
Monthly Subscription
for only
Level 2 Basic
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Synectics Plc SNX London Ordinary Share GB0007156838 ORD 20P
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 137.50 07:38:58
Open Price Low Price High Price Close Price Previous Close
more quote information »
Industry Sector

Top Investor Posts

simon gordon: Got a mention in Yorkshire Post tips for 2021 - 1/1/21: I’m going for surveillance firm Synectics, a company likely to see its shares soar as the world takes the first tentative steps back towards normality. As the vaccine is rolled out globally, crowds will return to cities. Casinos, a key market for Synectics, will reopen. New orders will start to land on the desk of Paul Webb, the company’s CEO, providing shareholders with shafts of light after a bleak period. Last month, Synectics reported growing interest from figures behind large government-related urban transport and critical infrastructure projects. Progress on the large and strategically important contract with Deutsche Bahn for Berlin’s S-Bahn has continued to go well, Synectics said. The contract is scheduled for deployment this month. The need for surveillance will grow in these watchful times, so Synectics is set to prosper in 2021. Https://
simon gordon: 2nd biggest shareholder in a pickle: City Wire - 18/11/20 Downing UK Micro-Cap suspends as losses mount Investors in the open-ended fund were blocked from trading earlier this month, with Maitland, the fund’s authorised corporate director (ACD), warning the fund was no longer viable ‘at its current size and liquidity profile’. ‘It is our opinion that the continued operation of the fund is therefore no longer in the best interests of investors,’ it said in a notice to investors. Maitland is now evaluating ‘a range of options to ensure an outcome that is in the best interests of investors’, including rolling the portfolio into another fund. ‘If no viable solution is found within a reasonable timescale, the ACD will seek regulatory approval for an orderly winding up of the fund and a controlled liquidation of the assets. In this scenario, our aim will be to return cash to investors as soon as possible,’ it added. Continued... Https://
arthur_lame_stocks: Well I don't expect things to be great for them for a while but I hope with quite a substantial pile of cash they are well placed to weather the storm and hopefully return to making operating profits of £5m a year in a couple of years time. I don't know about Whitehall. I've not heard of them before and you're never going to find out much about them being as they are based in Panama. They could just be an investor or maybe they are more like private equity and will bid for the whole lot.
dekle: Are Whitehall just an investor? Are they likely to buy a whole company? Problem for Synectics are a few fold including oil industry decline, bus security loss of contract and general lack of customers investing. Casinos have been their saviour up to now. This is all my opinion. I have held these for many years and hope I am completely wrong.
vb79: Wasn't the main man from SNX at a Paul Scott investor evening very recently promoting the company?
cfro: Good that Techinvest has napped SNX. I wouldnt be suprised if scsw doesnt latch on here too imo. Sp holding up well and its not pulled back much has it ?.......could be a real bun fight if investors start to notice this.
saucepan: Kombimatec: behind the scenes shenanigans are usually impenetrable to the private investor unfortunately - so no idea on that score; sorry. However,it looks to me as if strong support has been established. I suspect and hope that the tick-up just now will be the start of a significant move north.
davebowler: Westhouse; Strong Buy SNX.L / 272.5p / £47.88m / Likely % change in earnings forecasts: No Change Buying opportunity Synectics' share price has drifted back since the interim results in July while some of the comparator companies have seen their share prices rise. As the focus of investor attention switches to FY2013 in the coming months then we would expect that this share price underperformance will reverse. As has been flagged since it made the Indanet acquisition FY2013 would be the first year of a more meaningful profit contribution. This is reflected in the increase in our forecast PBT to £6.8m (30.4p of EPS) for FY2013 versus the £4.3m (19.1p of EPS) we expect for FY2012. At our 350p target price Synectics now stands at a small P/E discount to the peer group (13.5x vs 14.6x) that we feel is unwarranted hence the reiteration of our Strong Buy recommendation.
cat: director buying today pathetic attempt to shore stock price up. the company model is wrong and will likely fail. big pharma want traditional full service CROs. this co should never have come to market. Institutional investors could have been stung and will be lucky to get any of their money back pugugly i'll have a look.
papalpower: The web site is supposed to be upgraded this month, so that might lead to some news, no point in a trading update until you have the Investor Relations area of your web site done. Patience needed.
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210511 07:11:02